Maryland Biotechnology Roundtable: Does Having FDA As A Neighbor Help Small Firms?
As big pharma increasingly turns to biotech companies to help fill its pipeline, many smaller firms are seeing the possibility of large payoffs after years of work in a difficult capital environment. "The Pink Sheet" and "The Pink Sheet" DAILY recently brought together five CEOs of biotechnology companies based in Maryland to discuss the challenges they face.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth